Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer

Lung Cancer

Volumn 26, Issue 3, 1999, Pages 175-185

  Laohavinij, S ^a   Maoleekoonpairoj, S ^b   Cheirsilpa, A ^c   Maneechavakajorn, J ^a   Sirachainant, E ^d   Arpornvivat, W ^c   Jaisathaporn, K ^c   Ratanatharathorn, V ^d  

^a RAJAVITHI HOSPITAL   (Thailand)

^b PRAMONGKUTKLAO HOSPITAL   (Thailand)

^c NATIONAL CANCER INSTITUTE   (Thailand)

^d Fac Med   (Thailand)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer (NSCLC); Paclitaxel

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0033490817     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00089-6     Document Type: Article

References (33)

1. Cancer facts and figures, 1996. American Cancer Society.
2. Tanphaichitr V. Annual Report 1994. Ramathibodi Cancer Registry. Faculty of Medicine Ramathibodi Hospital. Mahidol. University 1994: 8-9.
3. Mountain C.F. The new international staging system for lung cancer. Surg. Clin. North. Am. 67(5):1987;925-935.
4. Mountain C.F. Prognostic implications of the international staging system for lung cancer. Semin. Oncol. 15:1988;236-245.
5. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 4:1986;702-709.
6. Rapp E., Pater J.L., Willan A. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multi-center randomized trial. J. Clin. Oncol. 6:1988;633-641.
7. Klastersky J., Sculier J.P., Lacroix H. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J. Clin. Oncol. 8:1990;1556-1562.
8. Bunn P.A. Review of therapeutic trials of carboplatin in lung cancer. Semin. Oncol. 16:1989;27-33.
9. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7:1989;1602-1613.
10. Murphy W.K., Fossella F.V., Winn R.J. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85:1993;384-388.
11. Chang A.Y., Kim K., Glick J. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology group results. J. Natl. Cancer Inst. 85:1993;388-394.
12. Langer C.J., Leighton J.C., Comis R.L. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis. J. Clin. Oncol. 13:1995;1860-1870.
13. Calvert A.H., Newell D.R., Gumbrell L.A. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756.
14. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
15. Miller A.B., Hoodgstraten B., Staquet M. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
18. Ramanathan R.K., Belani C.P. Chemotherapy for advanced non-small-cell lung cancer: past, present, and future. Semin. Oncol. 24:1997;440-454.
19. Johnson D.H., Paul D.M., Hande K.R. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J. Clin. Oncol. 14:1996;2054-2060.
20. van Warmerdam L.J.C., Huizing M.T., Giaccone G. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin. Oncol. 24(Suppl. 2):1997;97-104.
21. Kearns C.M., Belani C.P., Erkmen K. Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc. Am. Soc. Clin. Oncol. 14:1995;170. (Abstract 364).
22. Wild M.D., Walle U.K., Walle T. Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother. Pharmacol. 36:1995;41-44.
23. Siddiqui N., Boddy A.V., Thomas H.D. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer. 75:1997;287-294.
24. Kearns C.M., Egorin M.J. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin. Oncol. 24(Suppl. 2):1997;91-96.
25. Natale R.B. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small-cell lung cancer. Semin. Oncol. 23(Suppl 16):1996;51-54.
26. Roa V., Conner A., Mitchell R.B. Carboplatin and paclitaxel non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;398. (Abstract 1231).
27. Furuse K., Fukuoka M., Takada Y. A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non- small cell lung cancer (NSCLC): preliminary analysis. Proc. Am. Soc. Clin. Oncol. 16:1997;459a. (Absract 1649).
28. Langer C.J., Movsas B., Hudes R. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center Study 94-001. Semin. Oncol. 24(Suppl. 12):1997;89-95.
29. Eberhardt W, Wilke H, Stuschke M. Preoperative chemotherapy and concurrent chemoradiotherapy based on hyperfractionated accelerated radiotherapy followed by surgery in locally advanced (LAD) inoperable NSCLC stages IIIA and IIIB, Proc Am Soc Clin Oncol 1997; 16: 459a. Abstract 1650.
30. Choy H., Akerley W., Safran H. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1998;3316-3322.
31. Kelly K., Crowley J., Bunn P.A. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated non-small cell lung cancer (NSCLC): South West Oncology Group (SWOG) Trial. Proc. Am. Soc. Clin. Oncol. 18:1999;461a. (Abstract 1777).
32. Belani C.P., Natale P.B., Lee J.S. Randomized phase II trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;455a. (Abstract 1751).
33. Greco F.A., Hainsworth J.D. Paclitaxel (1 h infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multi-center phase II trial. Semin. Oncol. 24(Suppl. 12):1997;14-17.